位置:首页 > 产品库 > CRF(6-33)(human)TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CRF(6-33)(human)TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。

CRF(6-33)(human) TFA 是一种 CRF 结合蛋白配体 (CRF-BP) 抑制剂,与CRF-BP竞争性结合,但不与突触后 CRF 受体结合。CRF(6-33)(human) TFA 具有抗肥胖作用。
生物活性

CRF(6-33)(human) TFA is aCRF binding protein (CRF-BP)ligand inhibitor. CRF(6-33)(human) TFA competitively binds theCRF-BPbut not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect[1][2].

分子量

3334.68

Formula

C143H232F3N41O45S

Sequence Shortening

ISLDLTFHLLREVLEMARAEQLAQQAHS

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

 ContentsAssign value
Acidic amino acidAsp (D), Glu (E), and the C-terminal -COOH.-1
Basic amino acidArg (R), Lys (K), His (H), and the N-terminal -NH2+1
Neutral amino acidGly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)0

3.  Recommended solution:

Overall charge of peptideDetails
Negative (<0)1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024